Law360, New York (August 22, 2005, 12:00 AM ET) -- The Federal Circuit has ruled against Ohio-based generic drug manufacturer Owl Pharmaceutical, preventing the company from making a copycat version of prostate cancer drug Lupron Depot.
Lupron Depot, made by plaintiff Tap Holdings Inc., is a sustained-release prostate cancer treatment. Tap sued Owl in November 1999 after Owl completed an Abbreviated New Drug Application with the Food and Drug Administration to create a generic version of Lupron Depot.
In U.S. District Court for the Northern District of Ohio, Owl claimed the Tap patents were invalid, not...
Federal Circuit Rules Against Owl Pharma In Patent Dispute Over Prostate Cancer Drug
To view the full article, take a free trial now.
